Johnson and Johnson is to present new clinical research data on Zytiga - or abiraterone acetate - at the 2012 American Society of Clinical Oncology (Asco) Annual Meeting.
The drug is a kind of hormone therapy used in the treatment of advance prostate cancer and is typically taken once a day with a steroid called prednisolone.
It works by stopping the body's production of testosterone in the hopes of limiting cancer growth and Johnson & Johnson's findings will be presented alongside new information that has come to light regarding the investigational compounds ibrutinib and siltuximab.
William N. Hait, global head at Janssen research and development and head of the Oncology Therapeutic Area, explained the importance of the papers, as they will provide insight into a number of oncology disease states.
"These data presentations demonstrate our ongoing commitment to furthering the understanding of our compounds in a number of hematology and oncology settings," he commented.